Cardiol Therapeutics - CRDL Quick Ratio

Cardiol Therapeutics (CRDL) operates in the biopharma sector, facing the volatility typical of small-cap companies and regulatory hurdles in the treatment of pericarditis. This price chart confirms the current trend, where the indicator stands at 5.71. The business relies on the development of a pure anti-inflammatory agent for myocardial inflammation without psychotropic side effects. Currently, the strategy is focused on completing tests for new molecules to subsequently launch products on the US market.

This indicator assesses the ability of Cardiol Therapeutics (CRDL) to instantaneously settle short-term debts using only cash and accounts receivable, excluding illiquid inventories. By analyzing changes in the quick ratio, an investor can discern the real margin of safety for Cardiol Therapeutics, which is critically important for a biotech company in the clinical trial stage before securing monopoly pricing power for an orphan drug.